|
1
|
Monda L, Warnke R and Rosai J: A primary
lymph node malignancy with features suggestive of dendritic
reticulum cell differentiation. A report of 4 cases. Am J Pathol.
122:562–572. 1986.PubMed/NCBI
|
|
2
|
Sarkar R, Sharma S, Roy N, Shankar A and
Basu S: Follicular dendritic cell sarcoma of ileoceacal region in a
young woman: A rare case report with review of literature. Oman Med
J. 28(e055)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Saygin C, Uzunaslan D, Ozguroglu M,
Senocak M and Tuzuner N: Dendritic cell sarcoma: A pooled analysis
including 462 cases with presentation of our case series. Crit Rev
Oncol Hematol. 88:253–271. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Facchetti F, Simbeni M and Lorenzi L:
Follicular dendritic cell sarcoma. Pathologica. 113:316–329.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Jiang XN, Zhang Y, Xue T, Chen JY, Chan
ACL, Cheuk W, Chan JKC and Li XQ: New clinicopathologic scenarios
of EBV+ inflammatory follicular dendritic cell sarcoma: Report of 9
extrahepatosplenic cases. Am J Surg Pathol. 45:765–772.
2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chan AC, Chan KW, Chan JK, Au WY, Ho WK
and Ng WM: Development of follicular dendritic cell sarcoma in
hyaline-vascular Castleman's disease of the nasopharynx: Tracing
its evolution by sequential biops. Histopathology. 38:510–518.
2001.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cheuk W, Chan JK, Shek TW, Chang JH, Tsou
MH, Yuen NW, Ng WF, Chan AC and Prat J: Inflammatory
pseudotumor-like follicular dendritic cell tumor: A distinctive
low-grade malignant intra-abdominal neoplasm with consistent
Epstein-Barr virus association. Am J Surg Pathol. 25:721–731.
2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li W: The 5th edition of the World Health
Organization classification of hematolymphoid tumors. In: Leukemia.
Exon Publications, pp1-21, 2022.
|
|
9
|
Dalia S, Shao H, Sagatys E, Cualing H and
Sokol L: Dendritic cell and histiocytic neoplasms: Biology,
diagnosis, and treatment. Cancer Control. 21:290–300.
2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lorenzi L, Döring C, Rausch T, Benes V,
Lonardi S, Bugatti M, Campo E, Cabeçadas J, Simonitsch-Klupp I,
Borges A, et al: Identification of novel follicular dendritic cell
sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing.
Oncotarget. 8:16463–16472. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ibrahim A, Mir MH, Bagdadi FS, Sofi MA,
Khanday AR, Wani SA, Regmi SK, Bhat MH, Syed NA, Guru FR, et al:
Follicular dendritic cell sarcoma: A great mimicker with
unpredictable clinical course-experience from a tertiary care
cancer center in India. Front Oncol. 15(1544803)2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jain P, Milgrom SA, Patel KP, Nastoupil L,
Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, et al:
Characteristics, management, and outcomes of patients with
follicular dendritic cell sarcoma. Br J Haematol. 178:403–412.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen T and Gopal P: Follicular dendritic
cell sarcoma. Arch Pathol Lab Med. 141:596–599. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Feldman AL, Arber DA, Pittaluga S,
Martinez A, Burke JS, Raffeld M, Camos M, Warnke R and Jaffe ES:
Clonally related follicular lymphomas and histiocytic/dendritic
cell sarcomas: Evidence for transdifferentiation of the follicular
lymphoma clone. Blood. 111:5433–5439. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Soriano AO, Thompson MA, Admirand JH,
Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB and Pro B:
Follicular dendritic cell sarcoma: A report of 14 cases and a
review of the literature. Am J Hematol. 82:725–728. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li L, Shi YH, Guo ZJ, Qiu T, Guo L, Yang
HY, Zhang X, Zhao XM and Su Q: Clinicopathological features and
prognosis assessment of extranodal follicular dendritic cell
sarcoma. World J Gastroenterol. 16:2504–2519. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sasaki M, Izumi H, Yokoyama T, Kojima M
and Hosono A: Follicular dendritic cell sarcoma treated with a
variety of chemotherapy. Hematol Oncol. 35:905–908. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Krautler NJ, Kana V, Kranich J, Tian Y,
Perera D, Lemm D, Schwarz P, Armulik A, Browning JL, Tallquist M,
et al: Follicular dendritic cells emerge from ubiquitous
perivascular precursors. Cell. 150:194–206. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bay JO, Ray-Coquard I, Fayette J, Leyvraz
S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E,
Emile G, et al: Docetaxel and gemcitabine combination in 133
advanced soft-tissue sarcomas: A retrospective analysis. Int J
Cancer. 119:706–711. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Conry RM: Response of follicular dendritic
cell sarcoma to gemcitabine and docetaxel: Report of two cases and
literature review. Clin Sarcoma Res. 4(6)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen HM, Shen YL and Liu M: Primary
hepatic follicular dendritic cell sarcoma: A case report. World J
Clin Cases. 7:785–791. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Esmati E and Kolahdouzan K: Metastatic
follicular dendritic cell sarcoma treated with gemcitabine plus
docetaxel with an outstanding survival: A case report and review of
literature. Clin Case Rep. 9:473–476. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xu J, Sun HH, Fletcher CD, Hornick JL,
Morgan EA, Freeman GJ, Hodi FS, Pinkus GS and Rodig SJ: Expression
of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic
and dendritic cell disorders. Am J Surg Pathol. 40:443–453.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vermi W, Giurisato E, Lonardi S, Balzarini
P, Rossi E, Medicina D, Bosisio D, Sozzani S, Pellegrini W,
Doglioni C, et al: Ligand-dependent activation of EGFR in
follicular dendritic cells sarcoma is sustained by local production
of cognate ligands. Clin Cancer Res. 19:5027–5038. 2013.PubMed/NCBI View Article : Google Scholar
|
![Representative slices of
contrast-enhanced computed tomography illustrating tumour [asterisk
symbol (*)] (A) prior to gemcitabine/docetaxel chemotherapy and (B)
following 3 months of chemotherapy. (A) A well-defined, lobulated,
heterogeneously enhancing solid cystic mass lesion can be observed,
measuring 19.2x16.6x14.3 cm (obtained on October 3, 2022). (B) A
marked reduction in the size of same mass to 14x12.4x10 can be
observed (obtained on December 21, 2022). The mass lesion
illustrated by an asterisk (*) is not visible in first image of the
2nd row (LV5-SV1 level). The clear mesentery can be seen marked by
a white triangle. In the other two images, only small cystic masses
can be seen indicating significant reduction of overall tumour size
at these levels (Lower SV1 and SV2, respectively).](/article_images/mi/5/6/mi-05-06-00265-g01.jpg)
